Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering doubles litigation reserves

Executive Summary

Schering-Plough added $250 mil. to its litigation reserves in the second quarter largely in connection with the Boston U.S. Attorney's investigation of the company, Schering said July 21. Schering disclosed the criminal investigation into off-label promotion, Medicaid rebate evasion and obstruction of justice in 2003 (1"The Pink Sheet" June 2, 2003, p. 12). The company's total litigation reserves of $500 mil. represent the firm's estimate of the funds necessary to resolve the matter. The additional funds may also be used for separate inquiries by the U.S. Justice Department and several states into wholesale pricing practices...

You may also be interested in...



Schering-Plough Faces Criminal Case; Off-Label Promotion May Be One Count

A criminal investigation of Schering-Plough's marketing practices includes off-label promotion, the company disclosed May 30

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046130

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel